The US Food and Drug Administration (FDA) issued the first
Although the Ebola vaccine is alreadyReceived approval late last year and has proven effective in preliminary trials, the new drug could be useful in combating the ongoing outbreak in the Democratic Republic of the Congo and elsewhere in the world. The researchers also note that FDA approval could also boost the prospects for developing similar drugs for the coronavirus, which may become available even before a vaccine is available.
“This news underlines the importance of international cooperation in the fight against Ebola. We hope that further steps will lead to the fact that the number of patients worldwide will decrease. "
John Farley, director of the Office of Infectious Diseases at the FDA's Center for Drug Evaluation and Research.
Inmazeb contains a mixture of threemonoclonal antibodies that block the Ebola virus. The medicine was developed by Regeneron, which is also testing a coronavirus vaccine. In clinical trials, patients taking Inmazeb had a much lower chance of further complications, and the number of deaths decreased by several dozen times.
"Inmazeb" was tested for the first time duringclinical trials that were conducted in 2018 and 2019 during the Ebola outbreak in the Democratic Republic of Congo. The PALM study aimed to identify the most effective drug among four candidates. Intravenous Inmazeb received approval for use in adults and children after it was tested in a clinical trial on 382 volunteers infected with the Ebola virus.
Read also
On day 3 of illness, most COVID-19 patients lose their sense of smell and often suffer from a runny nose
There may be universes in black holes. We tell you about the new discovery
Scientists have found out why children are the most dangerous carriers of COVID-19